BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 26122035)

  • 21. Varicella-Zoster Virus and Herpes Simplex Virus 1 Differentially Modulate NKG2D Ligand Expression during Productive Infection.
    Campbell TM; McSharry BP; Steain M; Slobedman B; Abendroth A
    J Virol; 2015 Aug; 89(15):7932-43. PubMed ID: 25995251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MHC class I chain-related protein A shedding in chronic HIV-1 infection is associated with profound NK cell dysfunction.
    Nolting A; Dugast AS; Rihn S; Luteijn R; Carrington MF; Kane K; Jost S; Toth I; Nagami E; Faetkenheuer G; Hartmann P; Altfeld M; Alter G
    Virology; 2010 Oct; 406(1):12-20. PubMed ID: 20667578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance.
    Vulpis E; Loconte L; Peri A; Molfetta R; Caracciolo G; Masuelli L; Tomaipitinca L; Peruzzi G; Petillo S; Petrucci MT; Fazio F; Simonelli L; Fionda C; Soriani A; Cerboni C; Cippitelli M; Paolini R; Bernardini G; Palmieri G; Santoni A; Zingoni A
    J Extracell Vesicles; 2022 Jan; 11(1):e12176. PubMed ID: 34973063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.
    Salih HR; Antropius H; Gieseke F; Lutz SZ; Kanz L; Rammensee HG; Steinle A
    Blood; 2003 Aug; 102(4):1389-96. PubMed ID: 12714493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
    Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
    Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.
    Maccalli C; Scaramuzza S; Parmiani G
    Cancer Immunol Immunother; 2009 May; 58(5):801-8. PubMed ID: 19089424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and Function of NKG2D Is Impaired in CD8+ T Cells of Chronically HIV-1-Infected Patients Without ART.
    Giuliani E; Vassena L; Desimio MG; Buonomini AR; Malagnino V; Andreoni M; Doria M
    J Acquir Immune Defic Syndr; 2015 Dec; 70(4):347-56. PubMed ID: 26509932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.
    Stojanovic A; Correia MP; Cerwenka A
    Front Immunol; 2018; 9():827. PubMed ID: 29740438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NKG2D: A versatile player in the immune system.
    Jelenčić V; Lenartić M; Wensveen FM; Polić B
    Immunol Lett; 2017 Sep; 189():48-53. PubMed ID: 28414183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD155 on HIV-Infected Cells Is Not Modulated by HIV-1 Vpu and Nef but Synergizes with NKG2D Ligands to Trigger NK Cell Lysis of Autologous Primary HIV-Infected Cells.
    Davis ZB; Sowrirajan B; Cogswell A; Ward JP; Planelles V; Barker E
    AIDS Res Hum Retroviruses; 2017 Feb; 33(2):93-100. PubMed ID: 27296670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A nanoscale reorganization of the IL-15 receptor is triggered by NKG2D in a ligand-dependent manner.
    Bálint Š; Lopes FB; Davis DM
    Sci Signal; 2018 Apr; 11(525):. PubMed ID: 29636390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The HHV-6A Proteins U20 and U21 Target NKG2D Ligands to Escape Immune Recognition.
    Chaouat AE; Seliger B; Mandelboim O; Schmiedel D
    Front Immunol; 2021; 12():714799. PubMed ID: 34721381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity.
    Cerboni C; Neri F; Casartelli N; Zingoni A; Cosman D; Rossi P; Santoni A; Doria M
    J Gen Virol; 2007 Jan; 88(Pt 1):242-250. PubMed ID: 17170457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Viral inhibitors of NKG2D ligands: friends or foes of immune surveillance?
    Jonjić S; Polić B; Krmpotić A
    Eur J Immunol; 2008 Nov; 38(11):2952-6. PubMed ID: 18979514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
    Song H; Kim J; Cosman D; Choi I
    Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8
    Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F
    Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic Variability of Human Cytomegalovirus Clinical Isolates Correlates With Altered Expression of Natural Killer Cell-Activating Ligands and IFN-γ.
    Galitska G; Coscia A; Forni D; Steinbrueck L; De Meo S; Biolatti M; De Andrea M; Cagliani R; Leone A; Bertino E; Schulz T; Santoni A; Landolfo S; Sironi M; Cerboni C; Dell'Oste V
    Front Immunol; 2021; 12():532484. PubMed ID: 33897679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
    Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
    J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NKG2D ligands expression and NKG2D-mediated NK activity in Sezary patients.
    Dulphy N; Berrou J; Campillo JA; Bagot M; Bensussan A; Toubert A
    J Invest Dermatol; 2009 Feb; 129(2):359-64. PubMed ID: 18754036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.